XUAB2147-Phase I/II Study of Stereotactic Radiosurgery with Concurrent Administration of DNA Damage Response (DDR) Inhibitor (Olaparib) Followed by Adjuvant Combination of Durvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects with Breast Cancer Brain Metastases


Total Award Amount

  • 53698.00
  • Direct Costs

  • 39484.00
  • Sponsor Award Id

  • Contributor

  • Ahmed Elkhanany   Investigator  
  • Erica Stringer-Reasor M.D.   Principal Investigator  
  • Gabrielle Rocque M.D.   Investigator  
  • Katia Khoury   Investigator